Peripheral artery disease affects around 1 in 20 Americans over the age of 50, occurring when blood flow is limited by blocked arteries. The patients were treated with the implantation of a Human Acellular Vessel (HAV), a bioengineered tissue, to from Humacyte to facilitate revascularization.
Read More
Humacyte grows human blood vessels from human cells to serve surgeons for use in severe trauma cases like industrial accidents, gunshot wounds and the war in Ukraine.
Read More
Humacyte has secured up to $150 million in new capital – including $40 million upfront – from Oberland Capital Management as the firm moves to commercialize bioengineered human tissue. Here are the details.
Read More
It’s been a busy week for North Carolina public companies in tech and life science reporting financial results. Here’s a roundup.
Read More
Durham-based Humacyte is providing engineered blood vessels to multiple hospitals in Ukraine for treating wounded civilians and soldiers with vascular injuries suffered in the Russian invasion.
Read More
Humacyte, the emerging entrepreneurial life science firm focusing on the bioengineering of human tissue, reported a $31.6 million loss for its first quarter as a public company.
Read More
Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue, announdces the issuance of three additional U.S. patents covering its proprietary technology platform.
Read More
Humacyte, following a merger with a special purpose acquisition company (SPAC), is being traded on the public markets. Today, a prior financial backer announced it’s investing an additional $25M in the company, now that the merger has occurred.
Read More
Humacyte, a pioneer in the bioengineering of human tissue, is expecting to see stock begin trading on the Nasdaq today as part of a combination with Alpha Healthcare Acquisition Corp – and it is doing so with a new chair.
Read More
